Numenos is a techbio company that developed CURE, the world's first clinico-genomic foundation model for drug discovery and development. CURE successfully predicts which patients will benefit most from an experimental drug without dependence on a pharma company's proprietary internal data. This breakthrough enables pharma companies to dramatically improve the cost, speed, and success of their clinical trials and to identify novel targets and shelved drugs with the greatest potential for approval.